Arbutus Biopharma Corporation (ABUS)’s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) – The EN Herald

Arbutus Biopharma Corporation (NASDAQ:ABUS) and BioLineRx Ltd. (NASDAQ:BLRX) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Demonstrates Arbutus Biopharma Corporation and BioLineRx Ltd. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides us Arbutus Biopharma Corporation and BioLineRx Ltd.s net margins, return on equity and return on assets.

Institutional and Insider Ownership

The shares of both Arbutus Biopharma Corporation and BioLineRx Ltd. are owned by institutional investors at 43% and 27.13% respectively. About 40.87% of Arbutus Biopharma Corporations share are owned by insiders. Insiders Competitively, owned 3.46% of BioLineRx Ltd. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Arbutus Biopharma Corporation was more bearish than BioLineRx Ltd.

Summary

On 4 of the 7 factors BioLineRx Ltd. beats Arbutus Biopharma Corporation.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companys lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:

Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald